AstraZeneca Faces New Class-Action Suit Over Prilosec Patent Expiration

Law360, New York (January 27, 2005, 12:00 AM EST) -- U.K.-Swedish drug maker AstraZeneca is facing yet another class-action lawsuit over the way the company allegedly weaned patients off the ulcer drug Prilosec after its patent expired and on to its next-generation drug, Nexium.

The lawsuit, filed in Massachusetts Superior Court, alleges that AstraZeneca's deceptive marketing persuaded patients to switch from Prilosec, whose patent was about to expire, to Nexium, which is described as a nearly identical drug.

Plaintiffs in the Massachusetts lawsuit include Health Care for All and Commonwealth Care Alliance, both members of the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.